Vasculitis, a group of inflammatory disorders affecting blood vessels, has seen significant strides in its treatment landscape, with immunotherapy emerging as a promising approach. This article explores the current state of immunotherapy for vasculitis, delving into recent research developments and envisioning future directions in the pursuit of more effective and targeted treatments. Understanding the immunopathogenesis of vasculitis is crucial for developing targeted immunotherapies. Collaborations between immunologists, rheumatologists, and geneticists have deepened our knowledge of the immune mechanisms underlying vasculitic diseases. Recent research has unveiled specific immune pathways and cell types implicated in vasculitis, paving the way for more precise immunotherapeutic interventions. Collaborative efforts between biotechnologists and clinicians have led to the development of biologics and monoclonal antibodies that selectively target components of the immune system involved in vasculitis. Drugs like rituximab, tocilizumab, and belimumab have shown promising results in clinical trials, demonstrating their potential to modulate immune responses and alleviate vasculitic symptoms.
HTML PDFShare this article
Journal of Vasculitis received 83 citations as per Google Scholar report
